肿瘤预防与治疗2025，Vol.38Issue(10)：860-867,8.DOI:10.3969/j.issn.1674-0904.2025.10.002
HER2阳性乳腺癌新辅助治疗不同部位病理完全缓解的影响因素
Factors Influencing Pathologic Complete Response in Different Sites Fol-lowing Neoadjuvant Therapy for HER2-Positive Breast Cancer
摘要
Abstract
Objective:To explore the clinicopathological factors influencing site-specific pathologic complete response[total pathologic complete response(tpCR),breast pathologic complete response(bpCR),and axillary pathologic complete response(apCR)]following neoadjuvant therapy(NAT)in human epidermal growth factor receptor 2(HER2)-positive breast cancer to refine patient selection for local downstaging strategies.Methods:A retrospective analysis was conducted on HER2-positive breast cancer patients who received neoad-juvant chemotherapy combined with dual-targeted therapy and underwent surgery at Sichuan Cancer Hospital between April 2021 and April 2024 to evaluate the correlation between clinicopathological factors and tpCR,bpCR,and apCR.Results:A total of 207 patients were included in the analysis.The rates of tpCR,bpCR,and apCR were 58.94％,62.32％,and 82.13％,respectively.Univariate analysis revealed significant associations of HR status,HER2 status,and NAT regimen with tpCR,bpCR,and apCR(P＜0.05).Multivariable analysis identified HR-negative status(tpCR:OR=0.499,95％CI:0.275～0.907,P=0.023;bpCR:OR=0.517,95％CI:0.280～0.952,P=0.034;apCR:OR=0.416,95％CI:0.183～0.950,P=0.037),HER2 3+expression(tpCR:OR=0.356,95％CI:0.134～0.947,P=0.039;bpCR:OR=0.296,95％CI:0.112～0.788,P=0.015;apCR:OR=0.370,95％CI:0.141～0.976,P=0.045),and the TCbHP regimen(tpCR:OR=0.454,95％CI:0.237～0.867,P=0.017;bpCR:OR=0.449,95％CI:0.234～0.862,P=0.016;apCR:OR=0.373,95％CI:0.169～0.825,P=0.015)were inde-pendent predictors of tpCR,bpCR,and apCR after NAT.Conclusion:HER2-positive breast cancer patients with HR-nega-tive status,HER2 3+expression,and the TCbHP regimen are more likely to achieve tpCR,bpCR,and apCR following NAT,making them ideal candidates for this treatment approach,which demonstrates greater safety in this population.关键词
乳腺癌/人表皮生长因子受体/新辅助治疗/病理完全缓解/靶向治疗Key words
Breast cancer/Human epidermal growth factor receptor/Neoadjuvant therapy/Pathological complete re-sponse/Targeted therapy分类
医药卫生引用本文复制引用
王睿,王誉英,涂禧慧,曾娅玲,刘世伟,张蒲蓉..HER2阳性乳腺癌新辅助治疗不同部位病理完全缓解的影响因素[J].肿瘤预防与治疗,2025,38(10):860-867,8.基金项目
This study was supported by grants from Sichuan Anti-cancer Association(No.XH2023505).四川省抗癌协会临床科研基金(编号:XH2023505) （No.XH2023505）
